ImClone Receives $3 Million Payment From Merck

ImClone Systems Incorporated has received a $3 million payment from Merck KGaA for achieving a clinical development milestone under the Companies’ license agreement for ERBITUX(TM). Upon payment, ImClone Systems issued 150,007 shares of ImClone Systems’ common stock to Merck KGaA, representing the sale of these shares at a ten percent premium to market value as provided in the license agreement.

In December 1998, Merck KGaA licensed from ImClone Systems the right to develop ERBITUX outside of the U.S. and Canada and the co-exclusive right to develop ERBITUX in Japan.

The milestone relates to Merck KGaA’s ability to move forward with the clinical development of ERBITUX in the area of non-small cell lung cancer (NSCLC) based on data from four clinical studies of ERBITUX in combination with chemotherapy in patients with NSCLC.

The data from these studies, which included the Merck KGaA-sponsored Lung Cancer Cetuximab Study (LUCAS) randomized Phase II study, were presented during this year’s American Society of Clinical Oncology Annual Meeting, held in Chicago.

In the LUCAS study, the addition of ERBITUX to cisplatin and vinorelbine increased tumor response rates (53.3 percent vs. 32.3 percent) in 61 evaluable patients with chemotherapy-naive NSCLC.

“We are pleased that data from both ImClone Systems and Merck KGaA Phase II studies of ERBITUX in combination with chemotherapy in patients with non-small cell lung cancer have provided the clinical evidence needed to further the drug development program in this disease type,” stated Daniel S. Lynch, Acting CEO of ImClone Systems Incorporated.

ImClone Systems Incorporated is committed to advancing oncology care by developing a portfolio of targeted biologic treatments, designed to address the medical needs of patients with a variety of cancers.

Shop Steroids

dragon-pharmaceutical
A one-stop resource for ordering Dragon Pharma samples: Legit Tritren 150 – 24 hours a day, 7 days a week.

Dragon Pharma Reviews

Dragon Pharma operates four separate pharmacy businesses from its location in Europe. They offer in-store and mail order steroids: Cut Mix 150.

Procure Dragon Pharma LLC of Top Quality

Enantat 250 - Cheap Price

Administration: Injection
Main Ingredient: Testosterone Enanthate
Producer: Dragon Pharma
Package: 20 x 10 mL vial (250 mg/mL)
Price: 20 x $30.00

TriTren 150 - Discount Price

Administration: Injection
Basal Ingredient: Tri Trenbolone
Manufacturer: Dragon Pharma
Package: 30 x 10 mL vial (150 mg/mL)
Price: 30 x $55.00

Primobolan 200

Injectable Anabolic Steroid
Basic Component: Methenolone Enanthate
Made by: Dragon Pharma LLC
Package: 1 X 10 mL vial (200 mg/mL)

Cut Mix 150 - Bulk Price

Administration: Injection
Main Substance: Testosterone Propionate, Drostanolone Propionate, Trenbolone Acetate
Producer: Dragon Pharma
Unit: 10 x 10 mL vial (150 mg/mL)
Price: 10 x $52.00

Sustanon 350 - Bulk Price

Administration: Injection
Main Component: Testosterone Blend
Produced by: Dragon Pharma Labs
Pack: 10 x 10 mL vial (350 mg/mL)
Price: 10 x $45.00

NPP 150 [10 Vials]

Injectable Steroid for Muscle Growth
Active Ingredient: Nandrolone Phenylpropionate
Producer: Dragon Pharma Labs
10 Vials [10 mL per Vial (150 mg/ml)]
Price: 10 x $30.00 = $300.00 in Total

Parabolan 100

Active Constituent: Trenbolone Hexahydrobenzylcarbonate
Manufacturer: Dragon Pharmaceuticals
Package: 10 mL vial (100 mg/mL)

Enantat 400

Base Component: Testosterone Enanthate
Produced by: Dragon Pharma LLC
Unit: 10 mL vial (400 mg/mL)

TriTren 150

Basic Ingredient: Tri Trenbolone
Producer: Dragon Pharmaceutical
Unit: 10 mL vial (150 mg/mL)

Trenbolone 50

Basal Substance: Trenbolone Suspension
Produced by: Dragon Pharma LLC
Amount: 10 mL vial (50 mg/mL)

Enantat 400

Injectable Anabolic Steroid
Main Chemical Name: Testosterone Enanthate
Produced by: Dragon Pharmaceuticals
Package: 10 mL vial (400 mg/mL)

Turanabol

Branded by: Dragon Pharma LLC
Basic Substance: Chlorodehydromethyltestosterone
Package: 100 pills (20 mg/tablet)